Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia
Status:
Completed
Trial end date:
2020-07-17
Target enrollment:
Participant gender:
Summary
This randomized phase III trial studies how well methotrexate works compared to dactinomycin
in treating patients with low-risk gestational trophoblastic neoplasia. Drugs used in
chemotherapy, such as methotrexate and dactinomycin, work in different ways to stop the
growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. It is not yet known whether methotrexate is more effective than
dactinomycin in treating gestational trophoblastic disease.